GlassScriptPhysician profile
Salman Siddiqui
NPI 1437110053
$2,849.36
in general payments reported to CMS, 2019-2025
23 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $244 · 2021: $74.46 · 2022: $324 · 2023: $585 · 2024: $401 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $443.51 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Sunovion Pharmaceuticals INC. | $222.20 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $208.93 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $202.70 | 2019-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.76 | 2023-2025 | Caplyta |
| Lundbeck LLC | $196.00 | 2019-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $168.91 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $163.99 | 2020-2024 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Libtayo |
| Blueprint Medicines Corporation | $121.59 | 2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $120.97 | 2019-2024 | Uzedy |
| Rigel Pharmaceuticals, INC. | $117.90 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $110.45 | 2025 | Cobenfy |
| Shire North American Group INC | $103.88 | 2019 | |
| Neurocrine Biosciences, INC. | $67.80 | 2019-2025 | Ingrezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $60.74 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $50.57 | 2019 | |
| Neos Therapeutics, LP | $38.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $35.04 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $30.39 | 2021-2023 | Qelbree |
| Corium, LLC | $22.75 | 2022 | |
| Indivior INC. | $21.80 | 2024 | Perseris |
| Almatica Pharma LLC | $18.29 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Siddiqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.